Crossmark

Point mutation in <i>CD19</i> facilitates immune escape of B cell lymphoma from CAR-T cell therapy

Crossref DOI link: https://doi.org/10.1136/jitc-2020-001150

Published Online: 2020-10-06

Published Print: 2020-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Zhang, Zhen

Chen, Xinfeng

Tian, Yonggui

Li, Feng https://orcid.org/0000-0002-3895-0437
Zhao, Xuan

Liu, Jinyan

Yao, Chang

Zhang, Yi https://orcid.org/0000-0001-9861-4681
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03156101 at ClinicalTrials.gov

Documents that mention this clinical trial

Point mutation in <i>CD19</i> facilitates immune escape of B cell lymphoma from CAR-T cell therapy
https://doi.org/10.1136/jitc-2020-001150
Funding

Funding for this research was provided by:

the National Key Research and Development Program of China (2018YFC1313400)

the National Natural Science Foundation of China (U1804281, 81771781 and 81702810)
License Information

License valid from 2020-10-06